Bristol Myers offers a big premium to reel in Myokardia’s cardio pipeline with a $13B buyout

Five months after MyoKardia $MYOK swept its late-stage pivotal on its lead heart drug — highlighting its success with a precision med approach to cardiology — Bristol Myers Squibb is stepping up with a $13.1 billion buyout tied to a big premium. Bristol Myers is paying $225 a share […]

Click here to view original web page at endpts.com